Business

Alnylam stock poised to climb, reports say

John Maraganore is chief executive of Cambridge-based Alnylam.

Bloomberg News/File 2007

John Maraganore is chief executive of Cambridge-based Alnylam.

Advertisement

Alnylam Pharmaceuticals Inc., which describes itself as a leading RNAi therapeutics company, had its price objective raised by Needham & Co. to $40 from $28 in a research report released this week, Analyst Ratings Network reported. The firm has a “buy” rating on the stock. Piper Jaffray recently raised its price target to $42.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com